How to buy Aptose Biosciences stock (APTO)

Aptose Biosciences is a biotechnology business based in the US. Aptose Biosciences shares (APTO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.19 – a decrease of 0.05% over the previous week. Aptose Biosciences employs 35 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Aptose Biosciences stock

Buy Aptose Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Aptose Biosciences stock price (NASDAQ: APTO)

Use our graph to track the performance of APTO stocks over time.

Aptose Biosciences shares at a glance

• Key figures

Information last updated 2024-12-12.

Latest market close	$0.19
52-week range	$0.13 - $2.68
50-day moving average more info button	$0.33
200-day moving average more info button	$0.79
Wall St. target price	$2.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.92

Is it a good time to buy Aptose Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aptose Biosciences price performance over time

Historical closes compared with the close of $0.193 from 2024-12-13

1 week (2024-12-10)	1.95%
1 month (2024-11-15)	-47.11%
3 months (2024-09-17)	-52.32%
6 months (2024-06-17)	-77.82%

1 year (2023-12-15)	-91.92%
2 years (2022-12-16)	-97.55%
3 years (2021-12-17)	22.5
5 years (2019-12-17)	61.05

Aptose Biosciences financials

Gross profit TTM	$0
Return on assets TTM	-136.29%
Return on equity TTM	-694.13%
Profit margin	0%
Book value	$-0.37
Market Capitalization more info button	$10.9 million

TTM: trailing 12 months

Aptose Biosciences share dividends

We're not expecting Aptose Biosciences to pay a dividend over the next 12 months.

Have Aptose Biosciences's shares ever split?

Aptose Biosciences's shares were split on a 1:12 basis on 5 October 2014 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptose Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Aptose Biosciences shares which in turn could have impacted Aptose Biosciences's share price.

Aptose Biosciences share price volatility

Over the last 12 months, Aptose Biosciences's shares have ranged in value from as little as $0.13 up to $2.68. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptose Biosciences's is 1.364. This would suggest that Aptose Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aptose Biosciences overview

Aptose Biosciences Inc. , a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib.

Frequently asked questions

null
What percentage of Aptose Biosciences is owned by insiders or institutions?
Currently 16.385% of Aptose Biosciences shares are held by insiders and 16.685% by institutions. How many people work for Aptose Biosciences?
Latest data suggests 35 work at Aptose Biosciences. When does the fiscal year end for Aptose Biosciences?
Aptose Biosciences's fiscal year ends in December. Where is Aptose Biosciences based?
Aptose Biosciences's address is: 251 Consumers Road, Toronto, ON, Canada, M2J 4R3 What is Aptose Biosciences's ISIN number?
Aptose Biosciences's international securities identification number is: CA03835T2002 What is Aptose Biosciences's CUSIP number?
Aptose Biosciences's Committee on Uniform Securities Identification Procedures number is: 453219107